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Background
Although the current anti-retroviral therapy (ART) is truly
effective to prolong the patient's life, the long-term uptake
of drugs also appears to be raising issues such as trouble-
some side effects. Recently integrase (INT) inhibitors have
been added in a list of the medicines in addition to pro-
tease (PR) and reverse transcriptase (RT) inhibitors. Emer-
gence of multi-drug-resistant virus will be soon a serious
concern. We should present recommendations of the
regime(s) including INT inhibitors as early as possible
ideally by pre-clinical experiments. However, no good
animal model to test efficacies of anti-HIV-1 drugs espe-
cially by oral administration is available so far. Thus we
attempted to establish a new animal ART model in which
a combination of three groups of drugs can be tested using
monkeys.
Materials and methods
Two rhesus macaques infected with SHIV-pr that pos-
sesses the PR gene of HIV-1 [1] were used in this study.
When the monkeys were persistently infected, a mixture
of three drugs (nelfinavir, didanosine, and raltegravir)
contained in a solid diet was orally administered to them
twice a day for 4 weeks. Doses were determined by body
weight according to those for human use. Plasma viral
loads and CD4 cells were monitored during the whole
period of ART. Drug concentrations of raltegravir in
plasma were also measured by LC-MS.
Results
Plasma viral loads of two monkeys reached to 105-106
copies/ml before medication. The viral load of one mon-
key was suppressed below the detection limit by the 4th
week of ART, but quickly rebounded to the initial level
after the cease of medication. The trough of raltegravir was
sufficiently beyond the effective value. The load of
another monkey decreased one order of magnitude by the
2nd week of ART, but this animal gradually lost appetite
during ART and died of pneumonia thereafter.
Conclusion
The fact that one monkey died showing AIDS-like symp-
toms indicates that our SHIV-pr was not only replication-
competent but potentially pathogenic in monkeys. Over-
all, the present data suggest that this new animal ART
model was fairly good to evaluate efficacies of various
combinations of anti-HIV-1 drugs in vivo.
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